shutterstock_1652254300_taljat_david

Taljat David / Shutterstock.com

30 August 2022GenericsMuireann Bolger

Novartis sued over blockbuster heart failure drug

Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Novartis' Gilenya patent survives invalidity bid

12 May 2022 Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Court dismisses Regeneron’s antitrust countersuit against Novartis

3 February 2022 Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.

More on this story

Novartis' Gilenya patent survives invalidity bid

12 May 2022 Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Court dismisses Regeneron’s antitrust countersuit against Novartis

3 February 2022 Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.

More on this story

Novartis' Gilenya patent survives invalidity bid

12 May 2022 Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Court dismisses Regeneron’s antitrust countersuit against Novartis

3 February 2022 Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner